Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again

Why did Intercept shares tumble today?


Up 140%: Why Chelsea Therapeutics International Ltd. Is Soaring After-Hours

Why is Chelsea Therapeutics set to soar tomorrow?


The 3 Worst-Performing Big Pharma Stocks of 2013: LLY, NVO, SNY

Which big pharma stocks stumbled last year?


Up 61%: Why Intercept Pharmaceuticals Inc. Popped Again Today

Why Intercept Pharmaceuticals popped again today.


Down 29%: Why Chelsea Therapeutics International Ltd. Shares Crashed Today

Why did Chelsea Therapeutics shares tumble today?

Red Light, Green Light: 2 Things to Know Before Buying Teva Pharmaceutical Industries Ltd (ADR) Stock

What do investors need to know before investing in drugmaker Teva?


Roche's Genentech and the Culture of Innovation

Why Roche continues to impress investors and develop game-changing drugs.


The 5 Best-Performing Big Pharma Stocks of 2013: BMY, ABBV, RHHBY, JNJ, AZN

The pharmaceutical sector had a stellar 2013, but which stocks were the best?


Why Big Pharma Companies Need to Collaborate

The pharmaceutical industry has historically been very secretive, but collaborating is a key to innovation according to Bernard Munos.


Are Pharma Companies Too Big to Innovate?

Does size matter when it comes to innovation in the pharmaceutical industry?

How Mobile Technology Is Changing Medicine As We Know It

mHealth, or mobile health, could be one of the biggest buzzwords of 2014. But what is this fledgling field all about, and why are tech companies like Qualcomm and Verizon becoming major players in the health-care space?


GlaxoSmithKline: The World's Biggest Biotech Startup?

GlaxoSmithKline's discovery performance units make the company resemble a collection of biotech start-ups rather than a big pharma giant.


Sanofi: The Most Successful Comeback in Big Pharma History?

How did Sanofi CEO Chris Viehbacher help turn the pharmaceutical giant around?


How Gleevec Changed the Game for Novartis

Novartis' first rule of innovation -- forget the forecasts, focus on the science.


Is Culture the Solution to Big Pharma's Innovation Problem?

Innovation isn't a function of a big pocketbook or complex processes. Instead, companies should focus on culture to foster an entrepreneurial spirit.

Obamacare's Latest Enrollment Numbers: Good News or Bad News?

Are the latest Obamacare enrollment numbers too low, is the significant uptick in sign-ups encouraging, or is it simply too soon for consumers and investors to be concerned?


What Will the Fitbit Look Like in 5 Years?

Consumer demand for activity trackers is rising, and companies in this space continue to innovate. However, looking ahead over the next five years, what can companies like Fitbit come up with to help consumers monitor their health? What will Fitbit's devices be able to in the future?


Can Mobile Gaming Help Save Lives?

Video games have historically been associated with causing poor health, but can pharmaceutical companies turn mobile games into effective educational tools that can help patients manage chronic diseases?


Will Wearable Technology Be the Next Big Innovation in Health Care?

How wearable technology is already changing the way consumers think about their health.


Merck Stock: 3 Key Things to Watch Now

What are three key topics that Merck investors need to focus on right now?